GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2007

CSL Behring and Bayer Extend Agreement Related to Hemophilia

  • CSL Behring reached an agreement with Bayer HealthCare to continue the supply and distribution of a therapy for the treatment of hemophilia A. Bayer will provide Helixate® recombinant coagulation Factor VIII to CSL Behring through 2017.

    Additionally, Bayer was granted a license to intellectual property related to recombinant FVIII. At the same time, the companies settled outstanding litigation relating to the supply of recombinant Factor VIII.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »